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Abstract 
Aims: Endothelin-1 levels are raised in chronic thromboembolic pulmonary 
hypertension. Our aim in this study was to identify the presence of endothelin 
receptors in patients with CTEPH by analysing tissue removed at pulmonary 
endarterectomy. 
Main Methods: Pulmonary endarterectomy tissue cross-sections were analysed 
using autoradiography with [125I]-ET-1 using ligands selective for ETA or ETB to 
determine sub-type distribution. The precise cellular localisation of ETA and ETB 
receptors was determined using selective antisera to both sub-types and compared 
with haematoxylin and eosin, Elastic Van Gieson and smooth muscle actin labelled 
sections.  
Key findings: Two patterns of ET-1 binding were found. In sections with frequent 
recanalised channels, ET-1 bound to the smooth muscle cells surrounding the 
channels. In sections where there was less organised thrombus with no obvious re-
canalisation, minimal ET-1 binding was observed. Some contractile type smooth 
muscle cells not associated with recanalised channels and diffusely spread 
throughout the PEA material were associated with ET receptor antibody binding on 
immunohistochemistry. There was a greater expression of the ETA receptor type in 
the specimens. 
Significance: The presence of ET-1 receptors in the chronic thrombus in proximal 
CTEPH suggests ET-1 could act not only on the distal vasculopathy in the 
unobstructed vessels but may also stimulate smooth muscle cell proliferation within 
chronic clot.  The abundance of ET receptors within the tissue provides evidence 
that the ET pathway is involved in the pathology of chronic thrombus reorganisation 
leading to CTEPH providing a rationale for the repurposing of ET receptor 
antagonists in the treatment of this condition. 
 
 
 
Abstract word count = 251
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Introduction 
 
At present there is a limited understanding of the factors responsible for failure of 
resolution of acute pulmonary embolism and the subsequent development of chronic 
thromboembolic pulmonary hypertension (CTEPH). The raised pulmonary vascular 
resistance (PVR) in CTEPH is described by a two compartment model (Moser and 
Braunwald, 1973).  In some regions there are thromboembolic occlusions of the 
vascular lumen and a series of associated changes including including clot 
remodelling, collagen deposition and cellular hyperplasia. The 'closed' arterial tree 
distal to these obstructions is spared from exposure to high pressures. In other 
regions the 'open' arterial tree is exposed to high pressures and demonstrates 
pathological changes similar to those seen in pulmonary arterial hypertension (PAH); 
a distal vasculopathy with muscularisation of the distal precapillary arteries and 
intimal hyperplasia with medial hypertrophy of some larger pulmonary arteries 
(Moser and Braunwald, 1973). Currently, CTEPH is the only form of pulmonary 
hypertension for which there is a potential cure; pulmonary endarterectomy (PEA), 
through the surgical removal of proximal chronic thromboembolic material. (Pepke 
Zaba et al., 2011). 
  
Endothelin-1 (ET-1) is a potent vasoconstrictor. High levels of circulating ET-1 or its 
precursor big ET-1 have been demonstrated in patients with idiopathic PAH (Giaid et 
al., 1993; Langer et al., 2005; Stewart   et al., 1991 ).  The ET pathway is considered 
an important part of the pathology of idiopathic PAH and ET receptor antagonists 
such as bosentan and ambrisentan  (Maquire and Davenport, 2014, 2015)  and more 
recently macitentan (Davenport et al, 2016)  are used to try to slow progression. To 
date there is no ET antagonist licenced for use in CTEPH patients, although they are 
used ‘off-label’. The BENEFIT study did show a significant haemodynamic 
improvement with reduction in PVR, but no functional improvement with Bosentan 
(Jais et al., 2008). ET-1 acts via two receptors, ETA and ETB, which have different 
effects upon pulmonary artery smooth muscle cells. The ETA receptor activation 
results in vasoconstriction and smooth muscle cell proliferation. The ETB receptor 
activation prevents apoptosis of smooth muscle cells and causes vasodilatation via 
nitric oxide stimulation. ET-1 is a potent vasoconstrictor but is also a promoter of 
pulmonary artery smooth muscle cell proliferation (Davie et al., 2002). In agreement, 
Quarck et al., (2012) found that pulmonary arterial smooth muscle cells isolated from 
patients with CTEPH have enhanced proliferative properties.  
 
In patients with CTEPH, ET-1 levels are raised and have been shown to fall after 
PEA surgery (Reesink et al., 2006). After an acute pulmonary embolism there is 
obstruction of the pulmonary arteries by acute thrombus and elevated levels of ET-1 
(Sofia et al., 1997; Tsang et al., 2000). Elevated levels of ET-1 have also been 
observed in air embolus in animal models (Schmeck et al., 1998; Simon et al., 2003) 
and pretreatment with an ET antagonist ameliorated the haemodynamic change after 
acute pulmonary embolism (Schmek et al., 1998). In addition ET-1 is increased most 
in the muscularised pulmonary arteries (Lee et al., 2001). Intriguingly in human 
coronary arteries we have previously shown that recanalisation of thrombus is 
characterised by formation of new vessels which show intense endothelial ET-like 
immunoreactivity with ETA but not ETB receptors on the smooth muscle of 
recanalised vessels (Bacon et. al. 1996). Crucially, ET antagonists have been shown 
to block proliferation of smooth muscle in the intimal layer of vessels growing in 
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organ culture (Maguire et al., 2002The pathogenesis of CTEPH is complex but one 
question that arises is how much of the disease progression is driven by changes 
within the unresolved thrombus in parallel to the vasculopathy in the distal arterial 
bed. Despite many centres offering off-label use of ET receptor antagonist in the 
treatment of CTEPH, little is understood concerning the presence and underlying 
pattern  distribution of ET receptors within PEA material. Here we identify ET 
receptors in PEA material and provide a rationale for the ET receptor antagonists for 
treatment of CTEPH. 
Material and Methods 
Human tissue samples 
Human tissues were obtained with informed consent from the Papworth Hospital 
Research Tissue Bank (REC 08/H0304/56) and local approval (REC 05/Q0104/142). 
Tissue specimens were collected from consecutive patients undergoing PEA surgery 
for analysis. Information was collected prospectively based on factors that were 
considered relevant to the interpretation of the histological appearance and any ET 
receptor pattern. This included the use and type of targeted therapy for pulmonary 
hypertension prior to surgery, haemodynamics from at the time of diagnosis, the 
intraoperative macroscopic surgical assessment of the type of chronic 
thromboembolic pulmonary arterial obstruction (Jaimeson et al., 2000) and follow up 
post-operative haemodynamic measurements from assessment at least 3-6 months 
after PEA surgery. None of the patients had prior treatment with an ET receptor 
antagonist (to avoid the possible influence on ET receptor expression) (Hall et al., 
2011).   
 
During the PEA surgery the tunica intima and a superficial layer of tunica media was 
removed along with the luminal contents.  This tissue was then preserved in ice cold 
Krebs solution. Cross-sections were taken from the main endartectomy cast, 
normally one from the most proximal portion and other samples from smaller, more 
distal portions of the PEA material. [Fig. 1] These samples were kept at -80 ºC and 
batched for autoradiographical analysis and confocal microscopy. Serial 10µm 
sections were cut using a cryostat. Adjacent formalin fixed paraffin wax embedded 
blocks were taken for routine histological examination and immunohistochemistry. To 
determine the precise type of cell expressing the ET receptors, 
immunohistochemistry was performed to characterise the cell types that showed 
strong expression of the ET receptor in the ligand binding assays.  
 
 
Autoradiography 
Autoradiography was carried out using established techniques (Davenport and Kuc, 
2005). Briefly, sections were pre-incubated for 20 min at 23oC in assay buffer (50mM 
Hepes, 5mM MgCl2, 0.3% BSA, pH 7.4) prior t, California) to determine the 
distribution of all ET receptors.  ET receptor subtypes were visualised by incubating 
adjacent sections with [125I]-ET-1 (0.1nM) alone to measure total binding, and in the 
presence of either 0.2µM BQ3020 (to detect ETA) or with 0.1µM BQ123 (to detect 
ETB). Receptor occupancy curves based on the known specificity of each compound 
were used to determine the concentration of each ligand.  Non-specific binding was 
defined by incubating a further adjacent section with the radioligand in the presence 
of 1µM unlabelled ET-1 (Peptide Institute, Osaka, Japan).   
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Following incubation the sections were washed (3x5 minutes) in ice-cold Tris-HCl 
buffer (50 mM, pH 7.4), air dried and apposed, together with [125I]-ET-1 standards, to 
Kodak MR-1 autoradiography film for 3 days at room temperature. The films were 
processed and resulting autoradiograms photographed (Wild Heerbrugg microscope 
with Optim digital camera and Pixel Link OEM software).  
 
Statistical tests 
The degree of ET binding was assessed independently by two individuals and 
graded on the appearance of the autoradiogram alone. Broadly this was grouped 
into the following groups: none, <25%, 25%-50%, 50%-75%, >75%. Data were 
analysed using GraphPad Prism and difference between groups were assessed 
using a student’s t test. A p value of <0.05 was considered significant. 
 
Histopathology, Immunohistochemistry and Confocal microscopy 
Slides were prepared from cutting sections from each 4 µm wax embedded tissue 
block. After 48 hours in the oven to melt the wax and dry the tissue, the slides were 
put in PT modules (Dako Ltd, UK) for 1 hour at 98° C for antigen retrieval. After 
washing (with PBS solution) the slides were exposed to hydrogen peroxidase 3% 
blocking solution (Dako Ltd, UK) before being washed again with PBS. The primary 
antibody incubations were all for one hour at room temperature. Immunolabelling 
was performed using polyclonal rabbit anti-human ETA receptor antibody (ab84673, 
Abcam plc, Cambridge, UK); polyclonal rabbit anti- human ETB receptor antibody C- 
terminal (ab84182, Abcam plc, Cambridge, UK), monoclonal mouse anti- human 
smooth muscle actin (Dako Ltd, UK) and monoclonal mouse anti-human CD31 
(Dako Ltd, UK). Negative controls were incubated with EnVision Flex antibody 
diluent alone. Tissue sections were washed and incubated for 30 minutes with goat 
anti mouse/rabbit secondary antibodies EnVision Flex HRP (Dako Ltd, UK), washed 
and labelled using Flex DAB+ Chromogen (Dako Ltd, UK), washed and counter 
stained with Haematoxylin. The stained tissue sections were examined by a 
histopathologist with a special interest in pulmonary hypertension (MG).  A brief 
description of the histological appearance for each section was made based on the 
degree of obstruction of the vessel lumen, the presence of smooth muscle cells 
within the pulmonary artery lumen, the presence of endothelialised and recanalised 
channels with distinct organisation of smooth muscle cells surrounding these new 
channels. Serial frozen sections were also used for co-localisation studies using 
polyclonal rabbit anti-human ETA or polyclonal rabbit anti-human ETB receptor 
antibody C- terminal (ab84182, Abcam plc, Cambridge, UK), incubated with goat 
anti-rabbit IgG conjugated Texas red (red). Cytoskeleletal actin filaments were 
labelled using alexa488 (green) conjugated phalloidin (Invitrogen, UK) and nuclei 
labelled using 4',6-diamidino-2-phenylindole (DAPI; blue).    
Results 
Pulmonary endarterectomy specimens from 19 patients were collected; 14 male, 5 
female. The mean age was 63 ±9.7 years. One patient died in hospital and another 
patient did not return for post-operative follow-up. Table 1 shows the severity of the 
pulmonary hypertension and includes the surgical disease type (from the 
classification by Jaimeson et al., 2000), haemodynamics at the time of initial 
diagnosis and any pre-operative drug treatment. The haemodynamic variables 
demonstrate reasonably severe pulmonary hypertension (pulmonary vascular 
resistance 763 ± 377 dyn.s.cm-5). Ten patients had received pre-operative drug 
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treatment with a phosphodiesterase V inhibitor, sildenafil, prior to PEA surgery. 
Mean pulmonary artery pressure (mPAP) was higher (p=0.024) in the sildenafil 
treated group (50.90 ± 9.92 mmHg) compared to patients not on therapy (39.33 ± 
10.36 mmHg). PVR was similar between both groups. Pre-operative drug treatment 
did not appear to have any significant effect on ET receptor expression (data not 
shown). The majority of cases were Jaimeson classification type 1 or type 2. A 
typical example of a PEA specimen is included in Fig 1A. 
 
Table 1: Patient demographics 
Case 
Surgical 
classification Pre-PEA drug 
therapy 
Pre-PEA 
mPAP 
(mmHg) 
Pre-PEA 
PVR 
(dyn.s.cm-5) 
Post-PEA 
mPAP 
(mmHg) 
Post- PEA 
PVR 
(dyn.s.cm-5) Right Left 
1 1 2 Sildenafil 55 794 26 218 
2 1 1 None 50 816 17 146 
3 1 1 None 47 908 25 156 
4 2 3 Sildenafil 43 1162 37 549 
5 1 2/3 None 29 315 25 202 
6 2 3/4 Sildenafil 50 831 32 515 
7 1 2 None 53 733 24 151 
8 2 2 None 33 286 21 221 
9 3 3 Sildenafil 74 1561 § § 
10 2 2 None 33 297 27 204 
11 1 2 Sildenafil 43 491 38 304 
12 2 2 Sildenafil 44 1053 19 163 
13 1 1 Sildenafil 43 880 29 382 
14 2 2 None 28 222 20 166 
15 1 1 Sildenafil 47 888 43 545 
16 1 2 Sildenafil 60 1274 50 702 
17 1 1 Sildenafil 45 475 22 126 
18 2 2 None 31 400 # # 
19 2 3 None 50 1504 42 1002 
§ = died following PEA surgery. # = did not return for follow-up 
 
Histopathology of PEA material 
Forty three samples of tissue were taken for examination. Microscopically, the 
histological specimens were found to contain regions of fresh thrombus, intimal 
fibrosis with some degree of medial hyperplasia and organised thrombus in keeping 
with previous reports (Pietra et al. 1989; Bloor et al., 1993).  We observed overall 
appearance, approximate vessel dimensions, the degree of luminal obstruction and 
the number of recanalised channels. Proximal PEA material was comprised 
predominantly of matrix-rich fibrous tissue with little evidence of recanalization 
(Figure 1B). The approximate size of the native vessels examined ranged between 
about 40mm and 5mm in diameter. 6 sections were either fragments, long strips of 
tissue or had no discernible intimal layer. For the remaining thirty seven sections the 
degree of occlusion of the lumen of the native pulmonary artery was <50% in 8 
specimens, >50% in 8 specimens, 100% occluded in 21 specimens. Unsurprisingly 
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the smaller diameter tissue specimens displayed more intraluminal obstruction than 
the larger specimens. Fresh thrombus comprised fibrous tissue and loose 
fibromyxoid tissue with little evidence of organisation or matrix components. In more 
distal PEA material frequent recanalised channels were observed in many 
specimens, particularly evident in those of a smaller size (Fig. 1C). We next sought 
to the cell morphologies and to characterise the ET binding in the organising and 
non-organised PEA material.  
 
 
 
Figure. 1 (A) Typical PEA material Example of a PEA surgical specimen from the 
left lung of a patient with  CTEPH. Cross-sections taken from the central  proximal 
and distal tail portions are  indicated with dashed lines. (B), Typical findings of H&E 
stained proximal PEA material. (C) Typical findings of H&E stained distal PEA 
material, being highly organised with frequent neovessels (scale bars = 100µm).   
 
Autoradiographical ET receptor binding in PEA material 
Recent proximal thrombus with little evidence of neovascularization demonstrated no 
obvious pattern of expression for ETA or ETB receptors. In contrast, the 
autoradiograms showed ET binding was present in the majority of the distal 
pulmonary endarterectomy cross-sections. Specific ET receptor binding was 
observed in 32 of the 43 specimens.  Autoradiography showed that ETA 
predominated; all thirty two specimens express this sub-type. ETB binding was 
detected in twenty eight specimens and was more limited within the organized 
thrombus where ETB receptors co-localized with ETA receptors in all but one case.  
The tissue specimens with 100% occlusion showed the greatest proportion of ET 
receptor binding. These specimens were generally smaller in diameter and displayed 
a greater number of recanalised channels and a higher degree thrombus 
organisation. We estimated the % of the PEA specimen area to be either total ET, 
ETA or ETB positive in organised (predominantly proximal) and non-organised 
(predominantly distal PEA material. We found significantly higher levels of total ET 
and ETA receptors in organised PEA material compared to non-organised PEA 
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material (Fig. 2A). A highly organised PEA specimen is also included in Fig. 2 where 
total ET (B and C), ETA (D), ETB (E) are summarised. Serial staining of adjacent 
sections with H&E (F), SMA (G) and CD31 (H) suggested that ETB receptors were 
predominantly colocalised to areas also displaying SMA immunostaining. 
 
 
 
Figure. 2 We estimated the % of the PEA specimen area to be either total ET, ETA 
or ETB positive in organised (predominantly distal) and non-organised 
(predominantly proximal PEA material. We found significantly higher levels of total 
ET and ETA receptors in organised PEA material compared to non-organised PEA 
material (A). A highly organised PEA specimen is also included in Fig2 where total 
ET (B and C), ETA (D), ETB (E) are summarised. Serial staining of adjacent sections 
with H&E (F), SMA (G) and CD31 (H) suggested that ETA receptors were 
predominantly colocalised to areas also displaying SMA immunostaining (Scale bar = 
0.5mm). 
 
Immunohistochemistry and confocal characterisation of ET receptors in PEA 
material 
To further understand the distribution of ET receptors in PEA material, we performed 
immunohistochemistry for ETA and ETB receptors with anti-human SMA-α 
(to label smooth muscle cells and myofibroblasts) and anti-human CD31 to identify 
endothelial cells. Basal levels of ETA and ETB expression were observed in regions 
populated with secretory SMCs distributed throughout the non- or loosely-organised 
regions of fibromyxoid connective tissue in the proximal material (Figure 3A-D). 
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Figure 3 – PEA histopathology and ET receptor expression 
Representative images of the histopathology commonly observed in PEA material. 
Proximal PEA material  are collagen rich (B) with little obvious  pattern of (C) ETA or 
ETB (D) receptor expression.  Distal PEA material tends to be more orgainsed  with  
the presence of frequent recanlised neovessels (E) surrounded by loose fibromyxoid 
tissue as demonstrated by H&E. An Elastic Van gieson stain (F) demonstrates 
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diffuse collagen (red) surrounded by elastin  fibres (black).  Immunostaing for ETA 
(G) and ETB (H)reveal vascular expression of both receptor types. Neovessels 
present in distal PEA material each recapitulating the histological architecture of an 
artery, having arranged  contractile SMA-positive (fusiform) SMCs (I) and an 
endotheliased CD31 positive lumen (J) . Arrows demonstrate an endothelial cell 
lined neovessel surrounded by organised SMCs. Scale bars in A-D = 100µm. Scale 
bars in E-J = 50µm.   
 
The distal, smaller samples of PEA material commonly contained frequent 
recanalised neovessels surrounded by loose fibromyxoid tissue as demonstrated by 
H&E (Fig. 3E). An Elastic Van gieson stain (Fig. 3F) demonstrates diffuse collagen 
(red) surrounded by elastin fibres (black). Immunohistochemistry revealed strong 
levels of ETA (Fig. 3G) receptors and the presence of ETB (Fig. 3H) to be expressed 
by the neovessels. Neovessel throughout the distal PEA material each recapitulated 
the histological architecture of an artery, being having a contractile ring of SMA-α 
positive fusiform myofibroblasts (Fig. 3I)  with an endothelialised CD31-positive 
lumen (Figure 3J). Co-localisation studies using confocal microscopy confirmed ETA 
and ETB expression to be associated with Actin filaments in the muscularised portion 
of the recanalised vessel (Figure. 4).  
 
 
 
Figure 4 – ETA receptors are expressed by neovessels in PEA material 
To confirm the vascular expresion of ETA in distal PEA material we undertook 
confocal microscopy. (A) Cell nuclei were labelled using 4',6-diamidino-2-
phenylindole (DAPI; blue). (B) Cytoskeleletal actin filaments were labelled using 
alexa488 (green) conjugated phalloidin and (C) immunostained with polyclonal rabbit 
anti-human ETA labelled with Texas red (red). Co-localisation studies confirmed 
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strong ETA expression to be associated with Actin filaments in the muscularised 
portion of the recanalised vessel (D). Scale bars = 25µm.  
 
Discussion 
CTEPH is caused by chronic thromboembolic obstruction of the pulmonary 
vasculature and the more distal portions of this residual material can completely 
occlude the lumen and have been shown to contain frequent newly formed vascular 
channels (Yi et al., 2000; Abustini et al., 2002).  Our results show that ET receptors 
are present within the luminal obstructions removed from pulmonary artery branches 
during PEA surgery for patients with CTEPH. To our knowledge this is the first time 
this has been shown using autoradiography. A crucial advantage of using 
autoradiography to identify ET receptors is that the receptor must be expressed on 
the cell surface and functionally viable for the radiolabelled ET ligand to bind. This 
provides mechanistic evidence for circulating ET to play a role in the organised 
thrombus present in the larger pulmonary vessels. This novel observation implies 
that ET receptor antagonists could act on the pulmonary circulation in CTEPH at the 
level of the organising thrombus as well as in the small-vessel arteriopathy. Analysis 
of the distribution of the ET receptors in the specimens shows that the larger less 
occluded pulmonary arteries (>14mm diameter) had fewer recanalised channels 
present and a lower expression of ET receptors, in contrast to the smaller 
specimens.  
 
PEA specimen histology 
The heterogeneous nature of the pulmonary endarterectomy specimens from our 
patient cohort is unsurprising. Macroscopically the surgical team could identify 
differences in the tissues removed at PEA surgery (using the classification from 
Jaimeson). To overcome the heterogeneity of the tissue, it would have been 
desirable to use a greater number of cross-sections from the same patient. This 
would have potentially allowed for a more systematic analysis of the surgical tissue 
based on anatomical location. This was not possible to perform as the bulk of the 
extracted tissue was required for histological analysis for the patient and could 
therefore not be sent away for autoradiography. The histopathological appearance of 
the cross-sections through our PEA specimens is consistent with previous studies 
(Yi et al., 2000; Arbustini et al., 2002; Bloor et al., 1993) from pathological 
descriptions of CTEPH arising from post-mortem examinations, lung transplantation 
or from lung biopsies.   
 
ET receptor distribution ETA vs ETB 
The ETA receptor activation results in vasoconstriction and smooth muscle cell 
proliferation. The ETB receptor is located in the endothelium and its activation 
prevents apoptosis of smooth muscle cells and causes vasodilatation via release of 
nitric oxide.  The pattern of ETA and ETB receptor distribution in the lung has been 
previously demonstrated in animals (Kuc et al. 2006) and humans (Davie et al., 
2002; Davenport and Russell, 2001). In normal subject, congenital heart disease and 
idiopathic pulmonary hypertension subjects the larger calibre vessels showed 
predominant ETA expression with a relative increase in the ETB expression as the 
vessels narrow to 0.5-1mm diameter (while remaining <50% overall expression at 
this size). In the main pulmonary arteries >90% of ET expression demonstrated in 
the medial layer is ETA receptor. ETB vascular expression is seen to a lesser degree 
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in the small conduit arteries but at lower levels than seen for ETA.  Within the rest of 
the lung ETA expression is found in the parenchyma, airway smooth muscle and 
epithelial cells. ETB is seen in high density in airway smooth muscle and lower levels 
in lung parenchyma and airway submucosal glands.  
 
The results of our experiments on PEA specimens have shown that both receptors 
are expressed with more expression of ETA receptors compared with ETB. This 
would fit with the size of our cross-sections indicating that they are conduit artery 
size where ETA expression has been shown to be greater. The level of ETB 
expression we have found is without question less than ETA but in some specimens 
seemed greater than one might predict given data from congenital heart disease and 
idiopathic pulmonary arterial hypertension patients. Bauer et al (2002) have shown, 
in addition to elevated circulating plasma big ET-1 levels, elevated levels of ETB 
mRNA with no change in ETA mRNA in CTEPH specimens suggesting ETB is 
upregulated.  
 
Some similarities are thought to exist in the vascular remodelling seen both in 
CTEPH to those observed in IPAH (Peacock et al, 2006).  The implication of this on 
our findings is that ET receptors will also be present in smaller surgically 
inaccessible vessel obstructions hence ET receptor antagonists might have some 
effect on the SMCs in those obstructions. A randomised placebo controlled trial of 
ET receptor antagonist in patients with inoperable chronic thromboembolic 
pulmonary hypertension and patients with persistent pulmonary hypertension after 
pulmonary endarterectomy surgery (Jais et al., 2008) has shown statistically 
significant improvement in PVR and cardiac output but it is not possible to know 
whether this was because of effects on the distal vasculopathy or proximal 
obstructions described by the 'two compartment model of CTEPH'  (Moser and 
Braunwald et al., 1973).   
 
Conclusion 
This study demonstrates the presence of functionally viable ET receptors in the 
surgically extracted tissue from patients with CTEPH. The ET receptor was 
associated with smooth muscle cells, mainly the contractile phenotype of SMC that 
surrounds the recanalised channels and can be seen within the more organised 
chronic thrombus. Both the ETA and ETB receptors were found with the ETA receptor 
showing more expression. This shows a potential role for ET receptors to influence 
both compartments in CTEPH and generates questions about how ET antagonists 
might influence the pathological development of the chronic thrombus in CTEPH.  
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